Gal‐3, a β‐galactoside lectin with numerous functions (Dumic et al., 2006), is well known as a novel prognostic biomarker of heart failure (HF) with high predictive value for CV mortality and re‐hospitalization in HF patients (McCullough, 2014), whereas its low plasma concentration is associated with “successful” aging (Sanchis‐Gomar et al., 2016). This evidence concerns the gene LGALS3 and heart failure.